RecruitingNCT06376097

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation


Sponsor

AstraZeneca

Enrollment

1,000 participants

Start Date

Apr 19, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service.


Eligibility

Min Age: 45 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a lung cancer screening program using low-dose CT scans (a type of chest X-ray that uses less radiation) along with blood tests to look for early signs of lung cancer in people who are or were heavy smokers. **You may be eligible if...** - You are between 45 and 74 years old - You are a current smoker with at least 30 pack-years of smoking history, or a former smoker who quit less than 15 years ago - You have never participated in a lung cancer screening program before **You may NOT be eligible if...** - You have an advanced chronic disease (heart, lung, liver, kidney, or metabolic) that limits life expectancy or ability to have surgery - You are being treated for tuberculosis or a similar granulomatous disease - You have a history of cancer that could spread to the lungs - You are pregnant - You are unable to undergo a chest CT scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB)

Botucatu, São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06376097


Related Trials